|Bid||15.10 x 1200|
|Ask||15.12 x 900|
|Day's Range||14.80 - 15.24|
|52 Week Range||9.53 - 70.29|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 09, 2021 - Aug. 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.29|
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (Interna
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
Shares of the highly popular biotech stock ChemoCentryx (NASDAQ: CCXI) ticked up a few notches after a Wall Street analyst upgraded the stock to buy. Stifel analyst Dae Gon Ha thinks a recent development regarding the clinical-stage biotech's lead candidate is a pretty big deal that the rest of the stock market has mostly overlooked. Does recent receptivity from the Food and Drug Administration make ChemoCentryx a good stock to buy now, or is there another heartbreak on the horizon?